论文部分内容阅读
目的:探讨急性心肌梗死患者支架术后丹红注射液的抗血小板疗效。方法:急性心肌梗死患者42例支架术后常规治疗的同时,以丹红注射液抗血小板治疗,观察疗效,比较急性心肌梗死(AMI)患者治疗前后和同期40名健康体检者(对照组)血浆血小板活化因子水平。结果:急性心肌梗死支架术42例患者症状消失,治疗前血浆的血小板活化因子水平为(131.34±22.17)μg/L,明显高于对照组(40.69±11.26)μg/L。AMI组经治疗后血浆血小板活化因子水平为(74.59±16.17)μg/L,明显降低(P<0.01)。结论:AMI血小板处于活化状态,血小板活化因子可作为冠心病病情监测的有效指标,丹红注射液的抗血小板治疗有效,有助于提高急性心肌梗死患者支架术效果。
Objective: To investigate the anti-platelet effect of Danhong injection after stenting in patients with acute myocardial infarction. Methods: Forty-two patients with acute myocardial infarction (AMI) were treated with anti-platelet therapy by Danhong injection and 42 patients with acute myocardial infarction (AMI) before and after treatment were enrolled in this study. Forty-two healthy subjects (control group) Platelet activating factor levels. Results: The symptoms of 42 patients with acute myocardial infarction were disappeared. The plasma level of platelet activating factor before treatment was (131.34 ± 22.17) μg / L, which was significantly higher than that of the control group (40.69 ± 11.26) μg / L. The level of platelet-activating factor in AMI group was significantly lower than that in AMI group (74.59 ± 16.17 μg / L, P <0.01). Conclusion: AMI platelet is activated, platelet activating factor can be used as a valid indicator of coronary heart disease monitoring, Danhong injection of antiplatelet therapy is effective to improve the efficacy of stenting in patients with acute myocardial infarction.